Analytical Data
-
Gene name
CCL13
- Application
-
Alternative Names
CCL13；MCP4；NCC1；SCYA13；C-C motif chemokine 13
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99616
-
Expression Region
24-98aa
-
AA Sequence
QPDALNVPST CCFTFSSKKI SLQRLKSYVI TTSRCPQKAV IFRTKLGKEI CADPKEKWVQ NYMKHLGRKA HTLKT
-
Molecular Weight
9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL13, also known as C-C motif chemokine 13 or monocyte chemotactic protein 4 (MCP-4), is a member of the chemokine family that plays a crucial role in the immune response by attracting immune cells to sites of inflammation and infection. It is primarily produced by epithelial cells, monocytes, and macrophages, and has been implicated in various pathological conditions, including asthma, rheumatoid arthritis, and cardiovascular diseases. Research into CCL13 has intensified due to its potential as a biomarker for inflammatory diseases and its role in modulating the immune landscape. By studying CCL13 recombinant protein, scientists aim to elucidate its signaling pathways, understand its interactions with specific receptor types like CCR2 and CCR5, and explore its therapeutic implications. The production of recombinant CCL13 facilitates these studies, allowing researchers to investigate its biological functions and mechanisms in vitro and in vivo. This protein holds promise not only in advancing our understanding of immune responses but also in developing targeted therapies for inflammatory disorders. Therefore, CCL13 recombinant protein studies are vital for deciphering the complexities of immune cell recruitment and activation, contributing to the broader landscape of immunological research and therapeutic advancements.
